Risk/benefit assessment of vesnarinone in the treatment of end-stage heart failure: A seminar-in-printYOUNG, James.Drug safety. 2004, Vol 27, issn 0114-5916, 32 p., SUP1Serial Issue

Possible involvement of bone marrow stromal cells in agranulocytosis caused by vesnarinone treatmentAIZAWA, S; NAKANO, M; IMAI, T et al.Acta haematologica. 1997, Vol 98, Num 3, pp 140-146, issn 0001-5792Article

Effects of Vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: A report from the Vesnarinone TrialDESWAL, Anita; PETERSEN, Nancy J; FELDMAN, Arthur M et al.Chest. 2001, Vol 120, Num 2, pp 453-459, issn 0012-3692Article

Effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinoneFRYE, R. E; TAMMARA, B; COWART, T. D et al.Journal of clinical pharmacology. 1999, Vol 39, Num 11, pp 1177-1183, issn 0091-2700Article

Effects of vesnarinone on nitric oxide synthesis in rat cardiac myocytesKUROSAKI, K; IKEDA, U; MAEDA, Y et al.Cardiovascular research. 1998, Vol 38, Num 1, pp 192-197, issn 0008-6363Article

Precautions for use and adverse effects of vesnarinone: Potential mechanisms and future therapiesBERTOLET, Barry D.Drug safety. 2004, Vol 27, pp 11-18, issn 0114-5916, 8 p., SUP1Article

LC/MS/MS analysis of vesnarinone and its principal metabolites in plasma and urineTATA, P. N. V; SCHORNO, K. S; COWART, T. D et al.Journal of pharmaceutical and biomedical analysis. 1999, Vol 18, Num 6, pp 1037-1045, issn 0731-7085Article

Vesnarinone is a selective inhibitor of macrophage TNFα releaseKAMBAYASHI, T; MAZUREK, N; JACOB, C. O et al.International journal of immunopharmacology. 1996, Vol 18, Num 6-7, pp 371-378, issn 0192-0561Article

Optimising outcomes in end-stage heart failure: Differences in therapeutic responses between diverse ethnic groupsSASAYAMA, Shigetake.Drug safety. 2004, Vol 27, pp 19-24, issn 0114-5916, 6 p., SUP1Article

Inotropic agents and immune modulationSASAYAMA, Shigetake.Cardiovascular drugs and therapy. 2002, Vol 16, Num 3, pp 237-243, issn 0920-3206, 7 p.Article

Vesnarinone prolongs action potential duration without reverse frequency dependence in rabbit ventricular muscle by blocking the delayed rectifier K⁺ currentTOYAMA, J; KAMIYA, K; CHENG, J et al.Circulation (New York, N.Y.). 1997, Vol 96, Num 10, pp 3696-3703, issn 0009-7322Article

Effects of vesnarinone, a novel orally active inotropic agent with and immunosuppressive action, on experimental cardiac transplantation in ratsYOKOYAMA, H; MOMENI, R; GOLDSTEIN, C et al.Transplantation. 1996, Vol 62, Num 11, pp 1540-1543, issn 0041-1337Article

Vesnarinone, a differentiation inducing drug, directly activates p2l^waf1 gene promoter via Sp1 sites in a human salivary gland cancer cell lineOMOTEHARA, F; KAWAMATA, H; UCHIDA, D et al.British journal of cancer. 2002, Vol 87, Num 9, pp 1042-1046, issn 0007-0920, 5 p.Article

Neutropenia occurring during treatment with vesnarinone (OPC-8212)BERTOLET, B. D; WHITE, B. G; PEPINE, C. J et al.The American journal of cardiology. 1994, Vol 74, Num 9, pp 968-970, issn 0002-9149Article

AgranulocytosisYOUNG, N. S.JAMA, the journal of the American Medical Association. 1994, Vol 271, Num 12, pp 935-938, issn 0098-7484Article

The use of cytokine inhibitors. A new therapeutic insight into heart failureMATSUMORI, A.International journal of cardiology. 1997, Vol 62, pp S3-S12, issn 0167-5273, SUP1Conference Paper

Estrogen is associated with improved survival in aging women with congestive heart failure : Analysis of the vesnarinone studiesREIS, S. E; HOLUBKOV, R; YOUNG, J. B et al.Journal of the American College of Cardiology. 2000, Vol 36, Num 2, pp 529-533, issn 0735-1097Article

Effects of quinolinone derivative, vesnarinone, in combination with irradiation on human lung cancer cell linesFUJITA, M; TSUCHIDA, T; FUJITA, T et al.Oncology reports. 1999, Vol 6, Num 2, pp 353-357, issn 1021-335XArticle

Vesnarinone limits infarct size via adenosine-dependent mechanisms in the canine heartKITAKAZE, M; MINAMINO, T; FUNAYA, H et al.Circulation (New York, N.Y.). 1997, Vol 95, Num 8, pp 2108-2114, issn 0009-7322Article

Inhibitory effects of vesnarinone in the progression of myocardial damage in experimental autoimmune myocarditis in ratsISHIYAMA, S; HIROE, M; NISHIKAWA, T et al.Cardiovascular research. 1999, Vol 43, Num 2, pp 389-397, issn 0008-6363Article

Pharmacologic properties and clinical evaluation of the new inotropic agent OPC-8212 (vesnarinone)FELDMAN, A. M.Cardiovascular drug reviews (Print). 1993, Vol 11, Num 1, pp 1-11, issn 0897-5957Article

Vesnarinone restores contractility and calcium handling in early endotoxemiaTAKEUCHI, Koh; DEL NIDO, Pedro J; POUTIAS, Dimitrios N et al.Circulation (New York, N.Y.). 2000, Vol 102, Num 19, pp 365-369, issn 0009-7322, SUPArticle

Antitumor effect of a quinolinone derivative, vesnarinone, on mouse hepatomaFUJITA, M; FUJITA, T; HIGASHINO, K et al.Hepatology research. 2000, Vol 17, Num 1, pp 65-71, issn 1386-6346Article

A dose-dependent increase in mortality with vesnarinone among patients with severe heart failureCOHN, J. N; GOLDSTEIN, S. O; GREENBERG, B. H et al.The New England journal of medicine. 1998, Vol 339, Num 25, pp 1810-1816, issn 0028-4793Article

Effect of vesnarinone on cardiac function in patients with severe congestive heart failureSCHERRER-CROSBIE, M; COCCA-SPOFFORD, D; DISALVO, T. G et al.The American heart journal. 1998, Vol 136, Num 5, pp 769-777, issn 0002-8703Article